Escitalopram efficacy in depression: A cross-ethnicity examination of the serotonin transporter promoter polymorphism

Journal of Clinical Psychopharmacology

Volumn 34, Issue 5, 2014, Pages 645-648

  Bousman, Chad A ^a,b,c   Sarris, Jerome ^a,b   Won, Eun Soo ^d   Chang, Hun Soo ^e   Singh, Ajeet ^a,f   Lee, Hwa Young ^e   Ham, Byung Joo ^e   Tan, Chay Hoon ^g   Lee, Min Soo ^e   Ng, Chee H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d Korea University College of Medicine   (South Korea)

^e Soonchunhyang University   (South Korea)

^f DEAKIN UNIVERSITY   (Australia)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

antidepressant; efficacy; genotype; pharmacogenetic

Indexed keywords

ESCITALOPRAM; SEROTONIN TRANSPORTER; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; AGE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAMILTON SCALE; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; REMISSION; SEROTONIN TRANSPORTER GENE; SEX; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; GENETICS; MIDDLE AGED; PROMOTER REGION; PSYCHOLOGY; SINGLE BLIND PROCEDURE;

ADULT; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SINGLE-BLIND METHOD;

EID: 84907423655     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000165     Document Type: Article

References (22)

1. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22:239-258.
2. Won ES, Chang HS, Lee HY, et al. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology. 2012;66:221-229.
3. Ng C, Sarris J, Singh A, et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol. 2013;28:516-522.
4. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621-2624.
5. Kunugi H, Hattori M, Kato T, et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry. 1997;2:457-462.
6. Smits KM, Smits LJ, Schouten JS, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry. 2004;9:433-441.
7. Mauchly JW. Significance test for sphericity of a normal n-variate distribution. Ann Math Stat. 1940;11:204-209.
8. Greenhouse SW, Geisser S. On methods in the analysis of profile data. Psychometrika. 1959;24:95-112.
9. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000;61:403-408.
10. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19-36.
11. Srisurapanont M. Response and discontinuation rates of newer antidepressants: a meta-analysis of randomized controlled trials in treating depression. J Med Assoc Thai. 1998;81:387-392.
12. Nelis M, Esko T, Magi R, et al. Genetic structure of Europeans: a view from the North-East. PLoS One. 2009;4:e5472.
13. Maron E, Tammiste A, Kallassalu K, et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol. 2009;19:451-456.
14. Huezo-Diaz P, Uher R, Smith R, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry. 2009;195:30-38.
15. Hu XZ, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78:815-826.
16. Perroud N, Salzmann A, Saiz PA, et al. Rare genotype combination of the serotonin transporter gene associated with treatment response in severe personality disorder. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:1494-1497.
17. Uher R, McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis. Mol Psychiatry. 2008;13:131-146.
18. Wendland JR, Lesch KP, Newman TK, et al. Differential functional variability of serotonin transporter and monoamine oxidase a genes in macaque species displaying contrasting levels of aggression-related behavior. Behav Genet. 2006;36:163-172.
19. Martin J, Cleak J, Willis-Owen SA, et al. Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance. Mol Psychiatry. 2007;12:421-422.
20. Singh AB, Bousman CA, Ng C, et al. Antidepressant pharmacogenetics. Curr Opin Psychiatry. 2014;27:43-51.
21. Singh AB, Bousman CA, Ng CH, et al. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry. 2012;2:e198.
22. Ji Y, Biernacka JM, Hebbring S, et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J. 2013;13:456-463.